Pressure BioSciences Inc. (PBI) has announced “gross proceeds of $825,720 from the sale of 55,048 units to 10 accredited investors, including the company’s CEO and president, in the first tranche of the company’s $6 million Series C private placement.” Focused on making instruments to take samples of proteins, DNA, RNA, and small molecules for biological research, the Massachusetts-based life sciences company said each unit, sold at $15, consisted of one share of Series C convertible preferred stock and one warrant to buy 10 shares of common stock at $2.38 per share, expiring April 2014. See PBI Press Release and Mass High Tech, April 13, 2011.